Press Release / NEWS / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-T

NEWS

20/052025
IASO Bio Celebrates Grand Opening of Shanghai Waigaoqiao Global R&D Center and Successfully Hosts Forum on China's Cell Therapy Globalization
09/052025
IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel
28/032025
IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau

142025-02

IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
292025-01

IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Singapore Health Sciences Authority (HSA)
102024-12

IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH
082024-11

JAMA Oncology Publishes Phase 1b/2 Study Data on IASO Bio's Equecabtagene Autoleucel (Fucaso™) in the Treatment of Relapsed/Refractory Multiple Myeloma
302024-09

IASO Bio Scientist and Leading Chinese Physicians in Onco-Hematology Visit Hematology Center at the State University of Campinas, Brazil, to Explore Cooperation in Cancer Treatment
292024-09

IASO Bio Presented Comparative Clinical Outcomes on the Optimal Lymphodepletion Prior to Infution of Equecabtagene Autoleucel（FucasoTM）in Patients with Relapsed Refractory Multiple Myeloma at 2024 IMS Annual Meeting
272024-09

IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel（FucasoTM）at 2024 IMS Annual Meeting

Copyright © 2023 南京驯鹿生物技术股份有限公司　　　　苏ICP备2021047135号　　　　 Privacy Policy　|　Terms of Use